Jason S. Lewis, Ph.D.

Jason S. Lewis, Ph.D.

Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, USA

  • Biography
  • Research Interests
  • Publications

Professor Jason S. Lewis is the Emily Tow Jackson Chair at MSKCC in New York. He is the Vice Chair of Research and Chief Attending of the Radiochemistry & Imaging Sciences Service in the Department of Radiology. He holds a joint appointment in the Molecular Pharmacology and Chemistry Program and he is the Director of the Radiochemistry & Molecular Imaging Probe Core in the Sloan-Kettering Institute. Professor Lewis’ research program is a molecular imaging-based program focused on radiopharmaceutical development and their clinical translation. His research is supported by grants from the United States Department of Defense and the NIH.

Dr. Lewis is an inorganic and PET radiochemist with experience in the application of PET radiopharmaceuticals and molecular imaging agents for the diagnosis and therapy of cancer.

  1. Dilworth JR, Lewis JS, Miller JR, Zheng Y. The preparation of rhenium (V) oxo- and imido- complexes with Et2NCSNCOPh and Et2NCSNC(NH)Ph. The crystal and molecular structure of [ReOC1(PhCONCSEt2)2]. Polyhedron, 12:221-225, 1993.
  2. Dilworth JR, Lewis JS, Miller JR, Zheng Y. Rhenium complex of a triply deprotonated chelated thiosemicarbazide and its conversion to a nitride complex via a hydrazide intermediate. Crystal structure of [ReCI2(NH)(NHNH2)(PPh3)2]. Journal of the Chemical Society, Dalton Transactions, 1357-1361, 1995.
  3. Dilworth JR, Hutson AJ, Lewis JS, Miller JR, Zheng Y, Chen Q, Zubieta J. Complexes of potentially tri- and tetradentate phosphinothiol ligands with Mo, W, Re, Fe, Ru, Os, Rh, Ir and Ni. The crystal and molecular structures of [Me4N]2[Mo(CO)3{PhP(C6H4-2S)2}], [Re{PhP(C6H4-2S)2}2] and [IrH(CO){PhP(C6H4-2S)2}(PPh3)]. Journal of the Chemical Society, Dalton Transactions, 1093-1104, 1996.
  4. Lewis JS, Zweit J, Dearling JLJ, Rooney BC, Blower PJ. Copper(I)bisphosphine complexes as a basis for radiopharmaceuticals for positron emission tomography and targeted radiotherapy. Chemical Communications, 1093-1094, 1996.
  5. Lewis JS, Heath SL, Powell AK, Zweit J, Blower PJ. Diphosphine bifunctional chelators for low-valent metal ions. Crystal structures of the copper(I) complexes [CuClL12] and [CuL12][PF6] [L1 = 2,3-bis(diphenylphosphino)maleic anhydride]. Journal of the Chemical Society, Dalton Transactions, 855-863, 1997.
  6. Lewis JS, Zweit J, Blower PJ. Effect of ligand and solvent on chloride ion coordination in anti-tumour copper(I) diphosphine complexes: synthesis of [Cu(dppe)2]Cl and analogous complexes (dppe = 1,2-bis(diphenylphosphino)ethane). Polyhedron, 17:513-517, 1998.
  7. Anderson CJ, Jones LA, Bass LA, Sherman ELC, McCarthy DW, Cutler PD, Lanahan MV, Cristel ME, Lewis JS, Schwarz SW. Radiotherapy, toxicity and dosimetry of copper-64-labeled-TETA-octreotide in tumor bearing rats. Journal of Nuclear Medicine, 39:1944-1951, 1998.
  8. Dearling JLJ, Lewis JS, Mullen GED, Rae MT, Zweit J, Blower PJ. Design of hypoxia targeting radiopharmaceuticals: Selective uptake of copper-64 complexes in hypoxic cells in vitro. European Journal of Nuclear Medicine, 25:788-792, 1998.
  9. Dearling JLJ, Lewis JS, McCarthy DW, Welch MJ, Blower PJ. Redox-active metal complexes for imaging hypoxic tissues: structure-activity relationships in copper(II) bis(thiosemicarbazone) complexes. Chemical Communications, 22:2531-2533, 1998.
  10. Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. Journal of Nuclear Medicine, 40:177-183, 1999.
  11. Dearling JLJ, Mullen GED, Lewis JS, Rae MR, Zweit J, Welch MJ and Blower PJ. Hypoxia-Selective Copper-64 Complexes. In: Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine 5, Eds: M. Nicolini and U. Mazzi, 599-605, 1999.
  12. Lewis JS, Lewis MR, Srinivasan A, Schmidt MA, Anderson CJ. Structure-activity studies of Cu-64-labeled somatostatin analogs for diagnostic imaging and targeted radiotherapy. In: Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine 5, Eds: M. Nicolini and U. Mazzi, 53-59, 1999.
  13. Lewis JS, Srinivasan A, Schmidt MA, Anderson In vitro and in vivo evaluation of copper-64-TETA-Tyr3-octreotate: A new somatostatin analog with improved tissue target uptake. Nuclear Medicine and Biology, 26:267-273, 1999.
  14. Lewis JS, Lewis MR, Srinivasan A, Schmidt MA, Wang J, Anderson CJ. Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: Evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. Journal of Medicinal Chemistry, 42:1341-1347, 1999.
  15. McCarthy DW, Bass LA, Cutler PD, Shefer RE, Klinkowstein RE, Herrero P, Lewis JS, Cutler CS, Anderson CJ, Welch MJ. High purity production and potential applications of copper-60 and copper-61. Nuclear Medicine and Biology, 26:351-358, 1999.
  16. Lewis JS, Lewis MR, Cutler PD, Srinivasan A, Schmidt MA, Schwarz SW, Morris MM, Miller JP, Anderson CJ. Radiotherapy and Dosimetry of 64Cu-TETA-Tyr3-Octreotate in a Somatostatin Receptor-Positive Tumor-Bearing Rat Model. Clinical Cancer Research, 5:3608-3616, 1999.
  17. Lewis JS, Dearling JLJ, Sosabowski, Zweit J, Carnochan P, Kelland LR, Coley HM, Blower PJ. Copper bis(diphosphine) complexes: radiopharmaceuticals for the detection of multi-drug resistance in tumors by positron emission tomography. European Journal of Nuclear Medicine, 27:638-646, 2000.
  18. Lewis JS, Laforest R, Lewis MR, Anderson CJ. Comparative dosimetry of copper-64 and yttrium-90-Labeled somatostatin analogs in a tumor-bearing rat model. Cancer Biotherapy and Radiopharmaceuticals 15:593-604, 2000.
  19. Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, Bass LA, Lewis JS, McCarthy DW. Copper-64-TETA-Octreotide as a PET imaging agent for patients with neuroendocrine tumors. Journal of Nuclear Medicine, 42:213-221, 2001.
  20. Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ. Tumor uptake of copper-64-diacetyl-bis(N4-methylthiosemicarbazone): Effect of changes in tissue oxygenation. Journal of Nuclear Medicine, 42:655-661, 2001.
  21. Lewis JS, Laforest R, Buettner TL, Song S-K, Fujibayashi Y, Connett JM, Welch MJ. Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): An agent for radiotherapy. Proceedings of the National Academy of Sciences, 98(3):1206-1211, 2001.
  22. Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, Dempsey JF, Perez CA, Purdy JA, Welch MJ. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity modulated radiation therapy. International Journal of Radiation Oncology, Biology, and Physics, 49(4):1171-1182, 2001.
  23. Lewis JS, Wang M, Laforest R, Wang F, Erion JL, Bugaj JE, Srinivasan A, Anderson CJ. Toxicity and dosimetry of 177Lu-DOTA-Y3-octreotate in a rat model. International Journal of Cancer, 94:873-877, 2001.
  24. Obata A, Yoshimi E, Waki A, Lewis JS, Oyama N, Welch MJ, Saji H, Yonekura Y, Fujibayashi Y. Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent Cu-diacetyl-bis(N4-methylthiosemicarbazone)(Cu-ATSM) in tumor cells. Annals of Nuclear Medicine, 15(6):499-504, 2001.
  25. Lewis JS, Connett JM, Garbow JR, Buettner TL, Fujibayashi Y, Fleshman JW, Welch MJ Copper-64-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for the Prevention of Tumor Growth at Wound Sites following Laparoscopic Surgery: Monitoring Therapy Response with microPET and Magnetic Resonance Imaging. Cancer Research, 62:445-449, 2002.
  26. Dearling JLJ, Lewis JS, Mullen GED, Welch MJ, Blower PJ. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. Journal of Biological Inorganic Chemistry, 7:249-259, 2002.
  27. Li WP, Lewis JS, Kim JY, Bugaj JE, Johnson MA, Erion JL, Anderson CJ. DOTA-D-Tyr1-Octreotate: A Somatostatin Analogue for Labeling with Metal and Halogen Radionuclides for Cancer Imaging and Therapy. Bioconjugate Chemistry, 13(4):721-728, 2002.
  28. Vāvere A. L., Lewis JS and Welch MJ. Imaging of Antiangiogenic Treatments: Ti-45-transferrin MicroPET as a Surrogate Marker for Tumor Response. In: Technetium, Rhenium and other Metals in Chemistry and Nuclear Medicine 6, Eds: M. Nicolini and U. Mazzi, 101-105, 2002.
  29. Lewis JS, Herrero P, Sharp TL, Engelbach JA, Fujibayashi Y, Laforest R, Kovacs A, Gropler RJ, Welch MJ. Delineation of Hypoxia in Canine Myocardium using PET and Copper-diacetyl-bis(N4-methylthiosemicarbazone). Journal of Nuclear Medicine, 43:1557-1569, 2002.
  30. Scappaticci FA, Conteras A, Boswell CA, Lewis JS, and Nolan G. Polyclonal antibodies to xenogeneic endothelial cells induce apoptosis and block support of tumor growth in mice. Vaccine, 21:2667-2666, 2003.
  31. Dehdashti F, Grigsby RW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing Tumor Hypoxia in Cervical Cancer by Positron Emission Tomography with 60Cu-ATSM: Relationship to Therapeutic Response – A Preliminary Report. International Journal of Radiation Oncology, Biology, and Physics, 55(5):1233-1238, 2003.
  32. Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, Welch MJ, Siegel BA. In Vivo Assessment of Tumor Hypoxia in Lung Cancer with 60Cu-ATSM. European Journal Nuclear Medicine Molecular Imaging, 30:844-850, 2003.
  33. Mathias CJ, Lewis MR, Reichert DE, Laforest R, Sharp TL, Lewis JS, Yang Z-F, Waters DJ, Snyder PW,Low PS, Welch MJ and Green MA. Preparation of 66Ga- and 68Ga-labeled Ga(III)-Deferoxamine-Folate as Potential Folate-Receptor-Targeted PET. Radiopharmaceuticals. Nuclear Medicine Biology, 30:725-731, 2003.
  34. Aft RL, Lewis JS, Zhang F, Kim J, Welch MJ. Enhancing Targeted Radiotherapy by 64Cu-ATSM using 2-Deoxy-D-Glucose. Cancer Research, 63:5496-5504, 2003.
  35. Obata A, Yoshimoto M, Kasamatsu S, Naiki H, Takamatsu S, Kashikura K, Furukawa T, Lewis JS, Welch MJ, Saji H, Yonekura Y, Fujibayashi Y. Intra-tumoral distribution of 64Cu-ATSM: A comparison study with FDG. Nuclear Medicine Biology, 30:529-534, 2003.
  36. Obato A, Kasmatsu S, Lewis JS, Furukawa T, Takamatsu S, Toyahara J, Asai T, Welch MJ, Adams SG, Saji H, Yonekura Y, Fujibayashi Y. Basic characterization of 64Cu-ATSM as a radiotherapy agent. Nuclear Medicine Biology, 32:21-28, 2005.
  37. McQuade P, Martin KE, Castle TC, Went MJ, Blower PJ, Welch MJ, Lewis JS. Investigation into 64Cu labeled Bis(selenosemicarbazone) and Bis(thiosemicarbazone) complexes as Hypoxia Imaging Agents. Nuclear Medicine Biology, 32:147-156, 2005.
  38. O’Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, Burnazi E, Finn RD, Burgman P, Ruan S, Lewis JS, Welch MJ, Ling CC, Humm JL. Assessment of regional tumor hypoxia using 18F-FMISO and 64Cu-ATSM Positron Emission Tomography: A comparative study featuring MicroPET imaging, pO2 probe measurement, autoradiography and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. International Journal of Radiation Oncology, Biology, and Physics, 61(5):1493-1502, 2005.
  39. Laforest R, Dehdashti F, Lewis JS, Schwarz SW. Dosimetry of 60Cu-ATSM: a Hypoxia Imaging agent for PET. European Journal of Nuclear Medicine & Molecular Imaging, 32:764–770, 2005.
  40. Viehl CT, Becker-Hapak M, Lewis JS, Tanak Y, Liyanage UK, Linehan DC, Eberlein TJ, Goedegebuure PS. A Tat Fusion Protein-Based Tumor Vaccine for Breast Cancer. Annals of Surgical Oncology, 12(7):517-525, 2005.
  41. McQuade P, Miao Y, Yoo J, Quinn TP, Welch MJ, Lewis JS. Imaging of melanoma using 64Cu and 86Y-DOTA-ReCCSMH(Arg11), a cyclized peptide analog of α-MSH. Journal of Medicinal Chemistry, 48:2985-2992, 2005.
  42. Burgman P, O’Donoghue JA, Lewis JS, Welch MJ, Humm JL, Ling CC. Cell line dependent differences in uptake and retention of the hypoxia selective nuclear imaging agent Cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM). Nuclear Medicine Biology, 32(6):623-630, 2005.
  43. Laforest R, Sharp TL, Engelbach JA, Fettig NM, Herrero P, Kim J, Lewis JS, Rowland DJ, Tai Y-C, Welch MJ. Measurement of Input Functions in Rodents: Challenges and Solutions. Nuclear Medicine Biology, 32:679-685, 2005.
  44. Parry R, Schneider D, Hudson D, Parkes D, Xuan J-A, Newton A, Toy P, Lin R, Harkins R, Alicke B, Biroc S, Kretschmer PJ, Halks-Miller M, Klocker H, Zhu Y, Larsen B, Cobb RR, Bringmann P, Roth G, Lewis JS, Dinter H, Parry G. Identification of a Novel Prostate Tumor Target, Mindin/RG-1, for Antibody-Based Radiotherapy of Prostate Cancer. Cancer Research, 65:8397-8405, 2005.
  45. Yoo J, Tang L, Perkins TA, Rowland DJ, Laforest R, Lewis JS, Welch MJ. Preparation of High Specific Activity 86Y Using a Small Biomedical Cyclotron. Nuclear Medicine Biology, 32:891-897, 2005.
  46. Ruangma A, Bai B, Lewis JS, Sun X, Welch MJ, Leahy R, Laforest R. Three-dimensional maximum a posteriori (MAP) imaging with radiopharmaceuticals labeled with three Cu radionuclides. Nuclear Medicine Biology, 33:217-226, 2006.
  47. Kim J, Herrero P, Sharp TL, Laforest R, Rowland DJ, Tai Y-C, Lewis JS, Welch MJ. A Minimally Invasive Method of Determining Blood Input Function from PET Images in Rodents. Journal of Nuclear Medicine, 47:330-336, 2006.
  48. Herrero P, Kim J, Sharp TL, Engelbach JA, Lewis JS, Gropler RJ, Welch MJ. Assessment of myocardial blood flow using 15O-water and 1-[11C]-acetate in rats with small animal PET. Journal of Nuclear Medicine, 47:477-485, 2006.
  49. Welch MJ, Lewis JS, Kim J, Sharp TL, Dence CS, Gropler RJ, Herrero P. Assessment of myocardial metabolism in diabetic rats utilizing small animal PET imaging: A feasibility study. Journal of Nuclear Medicine, 47:689-697, 2006.
  50. Silva MJ, Uthgenannt BA, Rutlin JR, Wohl GR, Lewis JS, Welch MJ. In vivo skeletal imaging of 18F-fluoride with positron emission tomography reveals damage- and time-dependent responses to fatigue loading in the rat ulna (Cover Article). Bone, 39:229-236, 2006.
  51. Clifford T, Boswell CA, Biddlecombe GB, Lewis JS, Brechbiel MW. Validation of a Novel CHX-A” Derivative Suitable for Peptide Conjugation: Small Animal PET/CT Imaging using Yttrium-86-CHX-A”-Octreotide, Journal of Medicinal Chemistry, 49:4297-4304, 2006.
  52. Wei L, Easmon J, Nagi RK, Muegge BD, Meyer LA, Lewis JS. 64Cu-azabicyclo[3.2.2]nonane Thiosemicarbazone Complexes: Radiopharmaceuticals for the PET Imaging of Topoisomerase-II Expression in Tumors. Journal of Nuclear Medicine, 47:2034-2041, 2006.
  53. Jost SC, Wanebo JE, Song SK, Chicoine MR, Rich KM, Woolsey TA, Lewis JS, Mach RH, Xu J, Garbow JR. In Vivo Imaging in a Murine Model of Glioblastoma, Neurosurgery, 60:360-370, 2007.
  54. Wei L, Butcher C, Miao Y, Gallazzi F, Quinn TP, Welch MJ, Lewis JS. Synthesis and Biological Evaluation of Cu-64 labeled Rhenium-Cyclized α-MSH Peptide Analog Using a Cross-Bridged Cyclam Chelator. Journal of Nuclear Medicine, 48:64-72, 2007.
  55. Biddlecombe GB, Rogers BE, de Visser M, Parry JJ, de Jong M, Erion JL, Lewis JS. Molecular Imaging of Gastrin-Releasing Peptide Receptor-Positive Tumors in Mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-Bombesin(1-14). Bioconjugate Chemistry, 18:724-730, 2007.
  56. Wei L, Miao Y, Gallazzi F, Quinn T, Welch M, Vāvere AL, Lewis JS. Ga-68 labeled DOTA-rhenium cyclized α-melanocyte-stimulating hormone analog for imaging of malignant melanoma. Nuclear Medicine and Biology, 34:945-953, 2007.
  57. Vāvere AL, Kridel SJ, Wheeler FB, Lewis JS. 1-11C-Acetate as a PET Radiopharmaceutical for Imaging Fatty Acid Synthase Expression in Prostate Cancer. Journal of Nuclear Medicine, 49:327-334, 2008.
  58. Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone) Journal of Nuclear Medicine, 49:201-205, 2008.
  59. Dietz D W, Dehdashti FD, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, Ritter J, Lewis JS, Welch M J, Siegel B A. Tumor hypoxia detected by Positron Emission Tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Diseases of the Colon & Rectum, 51:1641-1648, 2008.
  60. Alidori S, Gioia Lobbia G, Papini G, Pellei M, Porchia M, Refosco F, Tisato F, Lewis JS, Santini C. Synthesis, in vitro and in vivo characterization of 64Cu(I)-complexes derived from hydrophilic tris(hydroxymethyl)phosphane and 1,3,5-triaza-7-phosphaadamantane ligands. Journal of Biological Inorganic Chemistry, 13:307-315, 2008.
  61. Vāvere AL, Lewis JS. Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines. Nuclear Medicine and Biology, 35, 273-279, 2008.
  62. Bonnitcha PD, Vāvere AL, Lewis JS, Dilworth JR. In vitro and in vivo evaluation of bifunctional bisthiosemicarbazone 64Cu-complexes for the positron emission tomography imaging of hypoxia. Journal of Medicinal Chemistry, 51:2985-2991, 2008.
  63. Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, Siegel BA. An Imaging Comparison of 64Cu-ATSM and 60Cu-ATSM in Cancer of the Uterine Cervix. Journal of Nuclear Medicine, 49:1177-1182, 2008.
  64. Zhou D, Sharp TL, Fettig NM, Lee H, Lewis JS, Katzenellenbogen JA, Welch MJ. Evaluation of a Bromine-76 Labeled Progestin 16α,17α-dioxolane for Breast Tumor Imaging and Radiotherapy: in vivo Biodistribution and Metabolic Stability Studies. Nuclear Medicine and Biology, 35:655-663, 2008.
  65. Dence CS, Ponde DE, Welch MJ, Lewis JS. Autoradiographic and Small-Animal PET Comparisons Between 18F-FMISO, 18F-FDG, 18F-FLT and the Hypoxic Selective 64Cu-ATSM in a Rodent Model of Cancer, Nuclear Medicine and Biology, 35:713-720, 2008.
  66. Papini G, Alidori S, Lewis JS, Reichert DE, Pellei M, Gioia Lobbia G, Biddlecombe GB, Anderson CJ, Santini C. Synthesis and Characterization of the Copper(II) Complexes of New N2S2-donor Macrocyclic Ligands: Synthesis and In Vivo Evaluation of the 64Cu Complexes. Dalton Transactions, 1:177-184, 2009.
  67. Wei L, Ye Y, Wadas T, Lewis JS, Welch MJ, Achilefu S, Anderson CJ. 64Cu-Labeled CB-TE2A and DiamSar Conjugated RGD Peptide Analogs for Targeting Angiogenesis: Comparison of their Biological Activity, Nuclear Medicine and Biology, 36:277-285, 2009.
  68. Schneider DW, Heitner T, Alicke B, Light DR, McLean K, Satozawa N, Parry G, Yoo J, Lewis JS, Parry R. In vivo biodistribution, PET imaging and tumor accumulation of [86Y] and [111In] anti-mindin/RG-1, engineered antibody fragments (scFv, diabody and IgE-CH4 miniantibody) in LNCaP tumor-bearing nude mice. Journal of Nuclear Medicine, 50:435-443, 2009.
  69. Wei L, Zhang X, Gallazzi F, Miao Y, Jin X, Brechbiel MW, Xu H, Clifford T, Welch MJ, Lewis JS, Quinn TP. Melanoma Imaging using 111In, 86Y and 68Ga labeled CHX-A’’-Re(Arg11)CCMSH. Nuclear Medicine and Biology, 36:345-354, 2009.
  70. Dong Z, Haibing Z, Jenks, C, Lewis JS, Katzenellenbogen J, Welch MJ. Bromination from the Macroscopic Level to the Tracer Radiochemical Level: 76Br Radiolabeling of Aromatic Compounds via Electrophilic Substitution. Bioconjugate Chemistry, 20:808-816, 2009.
  71. Holland JP, Jones MW, Bonnitcha PD, Lewis JS, Dilworth JR. Functionalised copper-64 complexes as precursors of potential PET imaging agents for neurodegenerative disorders. New Journal of Chemistry, 33, 1845-1852, 2009.
  72. Vāvere AL, Biddlecombe GB, Spees WM, Garbow JR, Wijesinghe D, Andreev OA, Engelman DM, Reshetnyak YK, Lewis JS. A Novel Technology for the Imaging of Acidic Prostate Tumors by Positron Emission Tomography. Cancer Research, 69:4510-4516, 2009.
  73. Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nuclear Medicine and Biology, 36:729-739, 2009.
  74. Bonnitcha PD, Bayly SR, Theobald MBM, Betts HM, Lewis JS, Dilworth JR. Nitroimidazole Conjugates of Bis(thiosemicarbazonato)64Cu(II) – Potential Combination Agents for the PET Imaging of Hypoxia. Journal of Inorganic Biochemistry, 102:126-135, 2010.
  75. Holland JP, Caldos-Lopes E, Divilov V, Longo VA, Taldone T, Zatorska D, Chiosis G, Lewis JS. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using 89Zr-DFO-trastuzumab, PLoS One, 5:e8859, 2010.
  76. Anderson H, Pillarsetty N, Cantorias M, Lewis JS. Improved synthesis of 2’-deoxy-2’-[18F]-fluoro-1-b-D-arabinofuranosyl-5-iodouracil ([18F]-FIAU). Nuclear Medicine and Biology, 37:439-442, 2010.
  77. Lebedev AY, Holland JP, Lewis JS. Clickable bifunctional radiometal chelates for peptide labeling, Chemical Communications 46:1706-1708, 2010.
  78. Ruggiero A, Holland JP, Lewis JS and Grimm J. Cerenkov luminescence imaging of medical isotopes, Journal of Nuclear Medicine, 50:1123-1130, 2010.
  79. Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. 89Zr-DFO-J591 for immunoPET imaging of prostate-specific membrane antigen (PSMA) expression in vivo. Journal of Nuclear Medicine, 51(8):1283-1300, 2010.
  80. Holland JP, Normand G, Ruggiero A, Lewis JS, Grimm J. Intra-operative imaging of PET radiotracers using Cerenkov luminescence emissions. Molecular Imaging, 10(3):177-86, 2011.
  81. Ruggiero A, Villa CH, Holland JP, Sprinkle SR, May C, Lewis JS, Scheinberg DA, McDevitt MR. Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. International Journal of Nanomedicine, 5:783-802, 2010.
  82. Zeglis BM, Pillarsetty N, Divilov V, Blasberg­ RA, Lewis JS. The Synthesis and Evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N­8-hydroxyoctanediamide ([18F]-FESAHA), A PET Radiotracer Designed for the Delineation of Histone Deacetylase Expression in Cancer. Nuclear Medicine and Biology, 38:683-696, 2011.
  83. Heneweer C, Holland JP, Divilov V, Carlin S, Lewis JS. Magnitude of enhanced permeability and retention (EPR) effect in tumors with different phenotypes – 89Zr-albumin as a model system, Journal of Nuclear Medicine, 52:625-633, 2011.
  84. Zeglis BM, Divilov V, Lewis JS. The Role of Metallation in the Topoisomerase IIα Inhibition and Anti-Proliferation Activity of a Series of α-Heterocyclic-4N-Substituted Thiosemicarbazones and their Cu(II) Complexes, Journal of Medicinal Chemistry, 54:2391-2398, 2011.
  85. Ruggiero A, Holland JP, Hudolin T, Shenker L, Koulova A, Bander NH, Lewis JS, Grimm J. Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immunoPET imaging. Journal of Nuclear Medicine, 52:1608-1615, 2011.
  86. Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, DaGama EMG, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, Vu LP, Zhao X, Zatorska D, Taldone T, Smith-Jones PJ, Alpaugh M, Gross SS,  Pillarsetty N, Ku T, Lewis JS, Larson SM, Levine R, Erdjument-Bromage H, Guzman ML, Nimer  SD, Melnick A, Neckers L, Chiosis G. Affinity-based proteomics reveal cancer-specific networks  coordinated by HSP90. Nature Chemical Biology, 7:818-826, 2011.
  87. Zeglis BM, Mohindra P, Weissmann GI, Divilov V, Hilderbrand SA, Weissleder R, Lewis JS. Modular Strategy for the Construction of Radiometalated Antibodies for Positron Emission Tomography Based on Inverse Electron Demand Diels-Alder Click Chemistry. Bioconjugate Chemistry, 22:2048-2059, 2011.
  88. Keliher EJ, Yoo J, Nahrendorf M, Lewis JS, Marinelli B, Newton A, Pittet MJ, Weissleder R. 89Zr-Labeled Dextran Nanoparticles Enable in vivo Macrophage Imaging. Bioconjugate Chemistry, 22:2383-2389, 2011.
  89. Dunphy MP, Zanzonico P, Veach D, Somwar R, Pillarsetty N, Lewis JS, Larson SM. Dosimetry of 18F-Labeled Tyrosine Kinase Inhibitor SKI-249380, a Dasatinib-Tracer for PET Imaging. Molecular Imaging & Biology, 14:25-31, 2012.
  90. Holland JP, Evans MJ, Rice SL, Wongvipat J, Sawyers CL, Lewis JS. Annotating MYC oncogene status with 89Zr-transferrin imaging. Nature Medicine, 18:586–1591, 2012.
  91. Ulmert HD, Evans MJ, Holland JP, Rice SL, Wongvipat J, Pettersson K, Abrahamsson P-A, Scardino PT, Larson SM, Lilja H, Lewis JS*, Sawyers CL*. Imaging androgen receptor signaling with a radiotracer targeting free prostate specific antigen (Cover Article). Cancer Discovery, 2, 320-327, 2012. (*denotes senior co-corresponding authors).
  92. Zhang H, Cantorias MV, Pillarsetty NVK, Burnazi EM, Cai S, Lewis JS. An improved strategy for the synthesis of [18F]-labeled arabinofuranosyl nucleosides. Nuclear Medicine and Biology, 39:1182-1188, 2012.
  93. Daumar P*, Wanger-Baumann CA*, Pillarsetty NVP, Fabrizio L, Carlin SD, Reshetnyak YK, Andreev OA, Lewis JS. Efficient 18F-Labeling of Large 37-Amino Acid pHLIP Peptide Analogues and their Biological Evaluation. Bioconjugate Chemistry, 1557-1566. 2012.
  94. Bailey GA, Price EW, Zeglis BM, Ferreira CL, Boros E, Lacasse MJ, Patrick BO, Lewis JS, Adam MJ, Orvig C.  H2azapa: a Versatile Acyclic Multifunctional Chelator for 67Ga, 64Cu, 111In, and 177  Inorganic Chemistry, 51:12575-12589, 2012.
  95. Abou DS, Thorek DLJ, Ramos NN, Pinkse MWH, Wolterbeek BT, Carlin SD, Beattie BJ, Lewis JS. 89Zr-labeled Paramagnetic Octreotide-Liposomes for PET-MR Imaging of Cancer. Pharmaceutical Research, 30(3):878-888, 2013.
  96. Evans MJ, Holland JP, Rice SL, Doran MG, Cheal SM, Campos C, Carlin SD, Mellinghoff IK, Sawyers CL and Lewis JS. Imaging tumor burden in the brain with 89Zr-transferrin (Cover Article). Journal of Nuclear Medicine, 59:90-95, 2013.
  97. Janjigian YY, Villegas N, Holland JP, Divilov V, Carbonetti G, Carlin SD, Gomes DaGama EM, Chiosis G, de Stanchina E, Lewis JS. Monitoring Afatinib Treatment in HER2 Positive Gastric Cancer with 18F-FDG and 89Zr-trastuzumab PET. Journal of Nuclear Medicine, 54:936–943, 2013.
  98. Andersen KF, Divilov V, Koziorowski J, Pillarsetty N, Lewis JS. Antilipolytic drug boosts glucose metabolism in prostate cancer. Nuclear Medicine and Biology, 40(4):524-8.
  99. Zeglis BM, Sevak KK, Reiner T, Mohindra P, Carlin SD, Zanzonico P, Weissleder, Lewis JS. A Pretargeted PET Imaging Strategy Based on Bioorthogonal Diels-Alder Click Chemistry. Journal of Nuclear Medicine, 54, 1389-1396, 2013.
  100. Yoshii Y, Furukawa T, Oyama N, Hasegawa Y, Kiyono Y, Nishii R, Waki A, Tsuji AB, Sogawa C, Wakizaka H, Fukumura T, Yoshii H, Fujibayashi Y, Lewis JS, and Saga T. Fatty Acid Synthase Is a Key Target in Multiple Essential Tumor Functions of Prostate Cancer: Uptake of Radiolabeled Acetate as a Predictor of the Targeted Therapy Outcome. PLoS ONE, 8:e64570, 2013.
  101. Viola-Villegas NT, Rice SL, Carlin S, Wu X, Evans MJ, Sevak K, Drobnjak M, Ragupathi G, Sawada R, Scholz WW, Livingston PO, Lewis JS. Applying PET to Broaden the Diagnostic Utility of the Clinically Validated CA19.9 Serum Biomarker for Oncology. (Cover Article). Journal of Nuclear Medicine, 54:1876-1882, 2013.
  102. Pickett JE, Nagakura K, Pasternak AR, Grinnell SG, Majumdar S, Lewis JS, Pasternak GW. Sandmeyer reaction repurposed for the site-selective, non-oxidizing radioiodination of fully deprotected peptides: Studies on the endogenous opioid peptide α-neoendorphin. Bioorganic & Medicinal Chemistry Letters, 4347-4350, 2013.
  103. Zeglis BM, Davis CB, Aggeler R, Kang HC, Chen A, Agnew BJ, Lewis JS. Enzyme Mediated Methodology for the Site-Specific Radiolabeling of Antibodies Based on Catalyst-Free Click Chemistry. Bioconjugate Chemistry, 24:1057-1067, 2013.
  104. Price EW, Zeglis BM, Cawthray JF, Ramogida CF, Ramos N, Lewis JS*, Adam MJ*, Orvig C*.  H4octapa-Trastuzumab: Versatile Acyclic Chelate System for 111In and 177Lu Imaging and Therapy.  Journal of the American Chemical Society (JACS). 135:12707-12721, 2013. (*denotes senior co-corresponding authors).
  105. Zhang H, Huang R, Pillarsetty NVK, Thorek DLJ, Vaidyanathan G, Serganova I, Blasberg RG, Lewis JS. Synthesis and Evaluation of [18F]Fluorine-labeled Benzylguanidine Analogs for Targeting the Human Norepinephrine Transporter. European Journal of Nuclear Medicine & Molecular Imaging, 41, 322-332, 2014.
  106. Gemignani ML, Patil S, Seshan VE, Sampson M, Humm JL, Lewis JS, Brogi E, Larson SM, Morrow M, Pandit-Taskar N. Feasibility and Predictability of Perioperative PET and Estrogen Receptor Ligand in Patients with Invasive Breast Cancer. Journal of Nuclear Medicine, 54:1697-1702, 2013.
  107. Price EW, Zeglis BM, Lewis JS*. Adam MJ*, Orvig C*.  H6phospa-trastuzumab: Bifunctional Methylenephosphonate-based Chelator with 89Zr, 111In and 177 Dalton Transactions, 43:119-131, 2014. (*denotes senior co-corresponding authors).
  108. Osborne JR, Green DA, Spratt DE, Lyashchenko S, Fareedy SB, Robinson BD, Beattie BJ, Jain M, Lewis JS, Christos P, Larson SM, Bander NH, Scherr DS. A Prospective Pilot Study of 89Zr-J591/PSMA Positron Emission Tomography (PET) in Men with Localized Prostate Cancer Undergoing Radical Prostatectomy. Journal of Urology, 191, 1439-1445, 2014.
  109. Emmetiere F, Irwin C, Viola-Villegas NT, Longo V, Cheal SM, Zanzonico P, Pillarsetty N, Weber WA, Lewis JS, Reiner, T. 18F-labeled-Bioorthogonal Liposomes for In Vivo Targeting. Bioconjugate Chemistry, 24:1784-1789, 2013.
  110. Andersen KF, Divilov V, Sevak K, Koziorowski J, Lewis JS, Pillarsetty NVK. Influence of Free Fatty Acids on Glucose Uptake in Prostate Cancer Cells. Nuclear Medicine & Biology, 41, 254-258, 2014.
  111. Tao J, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, Weitsman G, Barber P, Vojnovic B, Ellis H, Morse N, Viola-Villegas NT, Campos AB, Juric D, Hazra S, Singh S, Kim P, Bergamaschi A, Maheswaran S, Ng T, Penault-Llorca F, Lewis JS, Carey LA, Perou CM, Baselga J, Scaltriti M. Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer. Science Signaling (AAAS Science), 7 (318), ra29, 2014.
  112. Zhang H, Huang R, Cheung N-KV, Guo H, Zanzonico PB, Thaler HT, Lewis JS, Blasberg RG. Imaging the Norepinephrine Transporter in Neuroblastoma: A Comparison of [18F]-MFBG and 123I-MIBG in Neuroblastoma. Clinical Cancer Research, 20, 2182-2191, 2014.
  113. Zeglis BM. Emmetiere F, Pillarsetty N, Weissleder R, Lewis JS, Reiner T. Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid Phase Peptide Synthesis. Chemistry Open, 3, 48-53, 2014.
  114. Cheal SM, Punzalan B, Doran MG, Evans MJ, Osborne JR, Lewis JS, Zanzonico P, Larson SM. Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma. European Journal of Nuclear Medicine & Molecular Imaging, 41, 985-994, 2014.
  115. Viola-Villegas NT, Carlin SD, Ackerstaff E, Sevak KK, Divilov V, Serganova I, Kruchevsky N, Anderson M, Blasberg RG, Andreev OA, Engelman DM, Koutcher JA, Reshetnyak YK, Lewis JS. Understanding the Pharmacological Properties of a Metabolic PET Tracer in Prostate Cancer, Proceedings of the National Academy of Sciences (PNAS), 111, 7254-7259, 2014.
  116. Fernández-Tejada A, Chea EK, George C, Pillarsetty NVK, Gardner JR, Livingston PO, Ragupathi G, Lewis JS, Tan DS, Gin DY. Development of a Minimal Saponin Vaccine Adjuvant based on QS-21. Nature Chemistry, 6, 635-643, 2014.
  117. Viola-Villegas NT, Sevak KK, Carlin SD, Doran MG, Evans HW, Bartlett DW, Wu AM, Lewis JS. Non-invasive imaging of PSMA in prostate tumors with 89Zr-labeled huJ591 engineered antibody fragments: The faster alternatives. Molecular Pharmaceutics, in press, 2014.
  118. Deri MA, Ponnala S, Zeglis BM, Pohl G, Dannenberg JJ, Lewis JS, Francesconi LC. An Alternative Chelator for 89Zr Radiopharmaceuticals: Radiolabeling and Evaluation of 3,4,3-(LI-1,2-HOPO). Journal of Medicinal Chemistry, 57, 4849-4860, 2014.
  119. Brand C, Abdel-Atti D, Yachao Z, Carlin SD, Clardy SM, Keliher EJ, Weber WA, Lewis JS, Reiner T. In vivo imaging of GLP-1R with a targeted bimodal PET/fluorescence imaging agent.  (Cover Article). Bioconjugate Chem, 25, 1324-1330, 2014.
  120. Perez-Medina C, Abdel-Atti D, Zhang Y, Longo VA, Irwin CP, Ruiz-Cabello JM, Fayad ZA, Lewis JS, Mulder WMJ, Reiner T. A modular labeling strategy for in vivo positron emission tomography and near infrared fluorescence imaging of nanoparticle tumor targeting. Journal of Nuclear Medicine, in press, 2014.
  121. Adochite, R-C, Moshnikova A, Carlin SD, Guerrieri RA, Andreev OA, Lewis JS, Reshetnyak YK. Targeting Breast Tumors with pH (Low) Insertion Peptides. Molecular Pharmaceutics. 11, 2896-2905, 2014.
  122. Huang C-H, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, Kitzing T, Zhu N, de Stanchina E, Sawyers CL, Armstrong SA, Lewis JS, Sherr CJ, Lowe SW. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes & Development, 28, 1800-1814, 2014.
  123. Reiner T, Lewis JS, Zeglis BM. Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging. Journal of Visualized Experiments (JoVE), in press, 2014.
  124. Price EW, Brian BM, Cawthray JF, Lewis JS, Adam MJ, Orvig C. What a Difference a Carbon Makes: H4octapa vs. H4C3octapa, Ligands for In-111 and Lu-177 Radiochemistry. Inorganic Chemistry, in press, 2014.
  125. Pandit-Taskar N, O’Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack JC, Carrasquillo JA, Lefkowitz RA, Gonen M, Lewis JS, Holland JP, Cheal SM, Reuter VE, Osborne JR, Loda MF, Smith-Jones PM, Weber WA, Bander NH, Scher HI, Morris MJ, Larson SM. Zr-89-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging, in press, 2014.
  126. Daumar P, Zeglis BM, Ramos N, Divilov V, Sevak KK, Pillarsetty NVK, Lewis JS. Synthesis and evaluation of F-18-labeled ATP competitive inhibitors of topoisomerase II as probes for imaging topoisomerase II expression. European Journal of Medicinal Chemistry, 86, 769-781, 2014.